Hot Small Cap Stocks To Buy For 2018

The Q4 2016 earnings report for small cap 3D printing stock3D Systems Corporation (NYSE: DDD) is scheduled for before the market opens onTuesday (February 28th). It goes without saying that 3D printing / 3D printer stocks did not live up to the lofty expectations of investors. In the case of 3D Systems Corporation,anew CEO came onboard last April with him conducting a comprehensive review of the Companys operations while Q3 earnings werebetter-than-expected.

A technical chart for 3D Systems Corporationshows shares heading back towards an early October high:

A long term performance chart shows 3D Systems Corporation outperformingother 3D printing stocks like small caps ExOne Co (NASDAQ: XONE), Stratasys, Ltd (NASDAQ: SSYS)and Voxeljet AG (NYSE: VJET) with all four peaking around the same time in 2013/2014 before crashing back down with some signs of stabilization over the past year:

Hot Small Cap Stocks To Buy For 2018: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston

Hot Small Cap Stocks To Buy For 2018: Gerdau S.A.(GGB)

Advisors’ Opinion:

  • [By Manikandan Raman]

    On the news, Freeport-McMoRan surged 12 percent to $10.20 and Lundin Mining climbed 12 percent to $3.33. Gerdau SA (ADR) (NYSE: GGB) rose 19 percent to $1.23, Vale SA (ADR) (NYSE: VALE) advanced 18 percent to $4.85 and Banco Bradesco SA (ADR) (NYSE: BBD) gained 11 percent to $7.15.

Hot Small Cap Stocks To Buy For 2018: Sorrento Therapeutics, Inc.(SRNE)

Advisors’ Opinion:

  • [By William Romov]

    San Diego-based Sorrento Therapeutics Inc. (Nasdaq: SRNE) develops drugs to treat certain types of cancer and chronic cancer pain.

    On Jan. 6, company officials will present a new proprietary technology for the treatment of cancer. Analysts are calling this new technology a potential “game-changer.”

  • [By ]

    In the Lightning Round, Cramer was bullish on Spotify (SPOT) , Alkermes (ALKS) , Johnson & Johnson (JNJ) , Thermo Fisher Scientific (TMO) , Sorrento Therapeutics (SRNE) , NVIDIA (NVDA) , Nucor, Eli Lilly (LLY) and Kohlberg Kravis Roberts (KKR) .

  • [By ]

    Sorrento Therapeutics (SRNE) : “This is the kind of speculative stock that I like.”

    Geron (GERN) : “Let’s stick with high quality like Thermo Fisher Scientific (TMO) .”